retatrutide and semaglutide vs Semaglutide: Mechanism, Trials & Status Semaglutide vs Retatrutide

But for most, he says, there's an element of negative reinforcement

In 2024 the Food and Drug Administration added cardiovascular risk as a reason to be prescribed the GLP-1 drug Wegovy, grounded in results from a major trial that showed fewer heart attacks, strokes, and cardiovascular deaths in adults with obesity or overweight and established heart disease

Ongoing Support and Monitoring Regular follow-up appointments are essential to monitor your response to GLP-1 therapy, manage any side effects, and make any necessary adjustments to your treatment plan

Do not drive while youre taking pain medicine that may make you drowsy

Keep an eye on the expiration date and throw away any unused solution that remains after that date